(RTTNews) - Gilead Sciences, Inc. (GILD), a biopharmaceutical company, announced that it has reached an agreement to acquire investigational oral IL-23R inhibitor program, including lead asset HCXT-2001, from privately held PepStar Therapeutics Ltd.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。